CAR T or Bispecifics for CLL? Choosing the Right Immune Strategy for the Right Patient

The emergence of cellular and T-cell–engaging therapies is transforming the treatment landscape for relapsed and refractory chronic lymphocytic leukemia (CLL), raising important questions about optimal patient selection and sequencing. This debate-style session will examine the evolving roles of CAR T-cell therapy and bispecific antibodies in the management of high-risk, heavily pretreated CLL. Faculty will review the latest clinical trial and real-world data, comparing efficacy, durability of response, toxicity profiles, logistical considerations, and quality-of-life implications associated with each approach. Key factors influencing treatment decisions—including disease biology, prior therapy exposure, comorbidities, treatment goals, and access considerations—will be discussed. Attendees will gain practical, evidence-based insights into selecting the most appropriate immune strategy for individual patients in an increasingly complex therapeutic landscape.